Filing summary
Issuer and period: The supplied filing is Zaxis International Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 12, 2015—not a filing identified as Quantum X Labs Inc. The period is the full fiscal year; separate fourth-quarter results are not provided.
Business context and reporting period
Zaxis reported no current business operations and described itself as a shell company pursuing a business combination. Its historical electrophoresis-products business had ceased operations. In December 2014, Zaxis entered a non-binding MOU to pursue a reverse merger with Emerald Medical Applications Ltd., which develops early-stage melanoma detection and diagnosis technology. The proposed transaction remained subject to a definitive agreement and other conditions.
Financial results and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $28,125 | $41,200 |
| Interest expense | $20,745 | $10,200 |
| Debt discount amortization | $125,000 | $0 |
| Net loss | $173,870 | $51,400 |
| Reported operating cash flow | $1,000 | ($5,950) |
G&A declined 32%, mainly because of lower compensation expense. Interest expense increased 103%, which management attributed mainly to interest on advances converted into convertible notes. The 2014 net loss included $125,000 of non-cash debt-discount amortization, accelerated when convertible notes converted to shares. Gross and operating margins are not meaningful because the company had no revenue.
At December 31, 2014, cash was $1,000, current assets were $1,000, current liabilities were $163,784, and total liabilities were $186,159, including $22,375 of long-term notes payable. Working capital was negative $162,784. Current liabilities included $120,979 of advances payable and $35,305 of accrued interest. The filing says the company relied on management and affiliated parties for interim funding; it had no material cash resources. The auditors issued an unqualified opinion but included a going-concern explanatory paragraph citing substantial doubt about the company’s ability to continue.
Material changes, outlook, and risks
- Five holders converted $125,000 of notes into 4,125,000 shares during 2014; $35,295 of related accrued interest remained unpaid at year-end. The filing also describes $120,979 of advances as transferred to an unrelated party and $22,375 as converted into a nonconvertible note.
- The company’s leadership changed twice in late 2014: Jehuda Maimon was appointed and then removed after the Artsys reverse-merger proposal was abandoned; Liron Carmel became CEO, CFO, and sole director. Oded Gilboa was appointed CFO in February 2015.
- The Emerald MOU contemplated an $800,000 third-party raise. Emerald holders were to receive 45% of fully diluted shares after closing, plus up to 21% in milestone-based tranches. The transaction was not assured, and management said it might pursue an alternative combination.
- After year-end, Zaxis agreed to lend Emerald $90,000 and reported issuing 750,000 restricted units, each comprising one share and one warrant, at a post-reverse-split price of $0.40 per unit. These transactions do not establish that the proposed merger closed.
- Management warned that additional financing was necessary to continue as a going concern. Risks include inability to secure funding or complete a merger, dilution or control changes from new securities, dependence on a single future business, conflicts of interest, limited trading liquidity, and penny-stock restrictions. The company did not expect to pay dividends.
- Disclosure controls and internal control over financial reporting were reported ineffective because of a lack of segregation of duties. The filing reported no legal proceedings, contractual obligations, or off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer’s identity: the filing names Zaxis International Inc., while the request metadata names Quantum X Labs Inc.
- Check subsequent SEC filings for whether the Emerald definitive agreement, $800,000 financing, and reverse merger were completed, and review the terms and status of the $90,000 loan.
- Reconcile the share counts and capital structure, including the reported year-end shares, January 2015 reverse split, subsequent unit issuance, and March 2015 outstanding-share figures.
- Verify the composition, maturity, interest, and repayment status of year-end liabilities and the unpaid accrued interest.
- Review funding commitments and cash needs in light of the going-concern warning, and assess whether internal-control deficiencies were remediated.